BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC

被引：37
作者：
Ignatov, T. [1 ]
Poehlmann, A. [2 ]
Ignatov, A. [1 ,3 ]
Schinlauer, A. [2 ]
Costa, S. D. [1 ]
Roessner, A. [2 ]
Kalinski, T. [2 ]
Bischoff, J. [1 ]
机构：
[1] Univ Magdeburg, Dept Obstet & Gynecol, D-39108 Magdeburg, Germany
[2] Univ Magdeburg, Dept Pathol, D-39108 Magdeburg, Germany
[3] Univ Med Ctr Regensburg, Dept Obstet & Gynecol, Regensburg, Germany
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2013年 / 141卷 / 02期
关键词：
Breast cancer; BRCA1; Promoter methylation; TNBC; RNA EXPRESSION LEVELS; BREAST-CANCER; NEOADJUVANT CHEMOTHERAPY; CHEMOSENSITIVITY; MUTATION; SENSITIVITY; CISPLATIN;
D O I：
10.1007/s10549-013-2693-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The aim of the current study was to investigate the role of BRCA1 gene aberrations in sporadic triple-negative breast cancer (TNBC) and its impact on anthracycline-based therapy. BRCA1 promoter methylation was analyzed in 70 TNBC and compared with the clinical and pathologic characteristics. As a control group, we used 70 patients with non-TNBC. BRCA1 promoter methylation was observed in 65.2 % of patients and was similar in both groups. BRCA1 promoter methylation was associated with decreased intensity of BRCA1 protein expression (P = 0.002) and significant increase of median disease-free survival (DFS) of TNBC patients receiving adjuvant anthracycline-based chemotherapy (P = 0.001). Multivariate analysis revealed that BRCA1 promoter methylation remains a favorable factor in regard to DFS (HR 0.224; 95 % CI 0.092-0.546, P = 0.001) in TNBC after adjustment for other prognostic factors. In contrast, in non-TNBC, BRCA1 promoter methylation was not associated with any clinical and pathologic parameters. BRCA1 promoter methylation is a common mechanism of BRCA1 gene aberration in sporadic breast cancer and is predictive for better response to anthracycline-based therapies.
引用
收藏
页码：205 / 212
页数：8
相关论文
共 31 条
[1]   The role of BRCA1 in DNA double-strand repair: Past and present [J].
Caestecker, Kevin W. ;
Van de Walle, Gerlinde R. .
EXPERIMENTAL CELL RESEARCH, 2013, 319 (05) :575-587
[2]   BRCA1 methylation: a significant role in tumour development? [J].
Catteau, A ;
Morris, JR .
SEMINARS IN CANCER BIOLOGY, 2002, 12 (05) :359-371
[3]   A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer [J].
Chapppuis, PO ;
Goffin, J ;
Wong, N ;
Perret, C ;
Ghadirian, P ;
Tonin, PN ;
Foulkes, WD .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (08) :608-610
[4]   DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response [J].
Dejeux, Emelyne ;
Ronneberg, Jo Anders ;
Solvang, Hiroko ;
Bukholm, Ida ;
Geisler, Stephanie ;
Aas, Turid ;
Gut, Ivo G. ;
Borresen-Dale, Anne-Lise ;
Lonning, Per Eystein ;
Kristensen, Vessela N. ;
Tost, Joerg .
MOLECULAR CANCER, 2010, 9
[5]   Secondary mutations of BRCA1/2 and drug resistance [J].
Dhillon, Kiranjit K. ;
Swisher, Elizabeth M. ;
Taniguchi, Toshiyasu .
CANCER SCIENCE, 2011, 102 (04) :663-669
[6]   Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers [J].
Egawa, C ;
Motomura, K ;
Miyoshi, Y ;
Takamura, Y ;
Taguchi, T ;
Tamaki, Y ;
Inaji, H ;
Koyama, H ;
Noguchi, S .
BREAST CANCER RESEARCH AND TREATMENT, 2003, 78 (01) :45-50
[7]  
Fedier A, 2003, INT J ONCOL, V22, P1169
[8]  
Galizia E, 2010, ANAL QUANT CYTOL, V32, P24
[9]   Triple-negative breast cancer-current status and future directions [J].
Gluz, O. ;
Liedtke, C. ;
Gottschalk, N. ;
Pusztai, L. ;
Nitz, U. ;
Harbeck, N. .
ANNALS OF ONCOLOGY, 2009, 20 (12) :1913-1927
[10]   Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma -: 10-year follow-up data [J].
Goffin, JR ;
Chappuis, PO ;
Bégin, LR ;
Wong, N ;
Brunet, JS ;
Hamel, N ;
Paradis, AJ ;
Boyd, J ;
Foulkes, WD .
CANCER, 2003, 97 (03) :527-536
1234